Next Step In Global Convergence: FDA Looks To Make IMDRF Software Guidance Its Own
The US agency issued a draft guidance on clinical evaluation considerations for "software as a medical device." But FDA did not write the guidance internally. Instead it is an International Medical Device Regulators Forum document that was put together collaboratively by regulatory officials from across the globe. This is the first time FDA is attempting to wholesale adopt an IMDRF guidance document as its own.
You may also be interested in...
Hiring experts in artificial intelligence, cloud computing, cybersecurity and related fields is a central part of US FDA's recently announced "Digital Health Innovation Action Plan." The goal of the expanded team will be to make better regulatory decisions, issue new guidances and initiate a "pre-certification" pilot program for software.
The digital medtech sector is growing fast. As new companies enter the space, they are going to face oversight from a slew of government agencies and statutes. While FDA is an important focus for medtech, patient privacy and cybersecurity challenges for digital products raise other, significant compliance challenges. Medtech Insight discussed the range of hurdles the digital medtech industry faces with attorneys from Akin Gump.
The US agency was hoping to boost regulatory harmonization with the wholesale adoption of an international guideline on standalone medical device software, but medtech companies are worried that the guideline does not link up with US legislation and requirements.